XOMA Corporation (NASDAQ:XOMA) : During the past 4 weeks, traders have been relatively bearish on XOMA Corporation (NASDAQ:XOMA), hence the stock is down -17.58% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.68% relative to the S&P 500. The 4-week change in the price of the stock is -16.25% and the stock has fallen -4.47% in the past 1 week.
The company shares have dropped -87.53% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $4.93 and the one year low was seen on Jun 29, 2016. The 50-Day Moving Average price is $0.61 and the 200 Day Moving Average price is recorded at $0.83.
The stock has recorded a 20-day Moving Average of 3.8% and the 50-Day Moving Average is 16.72%.
XOMA Corporation (NASDAQ:XOMA): stock turned positive on Friday. Though the stock opened at $0.5434, the bulls momentum made the stock top out at $0.5697 level for the day. The stock recorded a low of $0.5412 and closed the trading day at $0.5488, in the green by 1.63%. The total traded volume for the day was 703,771. The stock had closed at $0.54 in the previous days trading.
In an insider trading activity,The officer (VP, Finance & Chief Financial) of Xoma Corp, Burns Thomas M. sold 19,249 shares at $0.79 on March 22, 2016. The Insider selling transaction had a total value worth of $15,207. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).